MIDATECH PHARMA
Media
May 22, 2017
Midatech announces progress update on brain cancer therapies

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Apr 11, 2017
Notice of Annual General Meeting 2017
Apr 4, 2017
Audited financial results for the year ended 31 December 2016

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Mar 10, 2017
Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

~ Q-Octreotide will become Midatech’s first Sustained Release product candidate manufactured in house at its state-of-the-art... read more >

Jan 20, 2017
Trading Update

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Nov 22, 2016
Midatech provides update on agreement with Emergex Vaccines

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Nov 15, 2016
Midatech selects MTR104 candidate for treatment of liver cancer

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Sep 30, 2016
Commencement of First in Human Immunotherapy Study Using Gold Nanoparticle Technology

Midatech (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in... read more >

Sep 21, 2016
Midatech Pharma US Announces Partnership with R-Pharm US to Co-promote Zuplenz® (ondansetron) oral soluble film and Oravig® (miconazole) orally-dissolving buccal tablet

~ Partnership provides additional reach and frequency within the oncology market ~

~ Deal broadens Zuplenz... read more >

Sep 2, 2016
Interim results for the six months ended 30 June 2016

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Aug 10, 2016
Trading Update and Notice of Results

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Jul 7, 2016
Grant funding received to explore Midatech’s gold nanoparticle technology in immunotherapy

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

May 18, 2016
Midatech Pharma announces clinical pipeline update

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), today announces an update on its clinical pipeline developments.
 
Midatech is working on... read more >

May 11, 2016
AGM Statement and Update on Trading

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), today will host its Annual General Meeting at Panmure Gordon & Co, One New Change, London, EC4M... read more >

Apr 26, 2016
Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide

~ Release profile of Midatech’s Q-Octreotide compared favourably with the reference product and current market... read more >

Apr 21, 2016
Midatech achieves positive dosing data for OpsiSporin Uveitis programme

~ Programme is delivering on track for an IND in H2 2017 ~

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the... read more >

Apr 13, 2016
Audited financial results for the year ended 31 December 2015

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Apr 11, 2016
Midatech’s Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US

~ Midatech further expands its commercial footprint in US, supporting the Zuplenz® launch ~

Midatech Pharma... read more >

Feb 29, 2016
Midatech Pharma Recognises International Rare Disease Day 2016

~ Dosing has commenced with MTX110 for DIPG on a named patient basis ~

Midatech Pharma (AIM: MTPH, Nasdaq:... read more >

Jan 6, 2016
Pre-close Trading Update

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Jan 4, 2016
Midatech signs licencing agreement with Emergex Vaccines

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

 

Media
May 22, 2017
Midatech announces progress update on brain cancer therapies

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Apr 11, 2017
Notice of Annual General Meeting 2017
Apr 4, 2017
Audited financial results for the year ended 31 December 2016

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Mar 10, 2017
Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

~ Q-Octreotide will become Midatech’s first Sustained Release product candidate manufactured in house at its state-of-the-art... read more >

Jan 20, 2017
Trading Update

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Nov 22, 2016
Midatech provides update on agreement with Emergex Vaccines

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Nov 15, 2016
Midatech selects MTR104 candidate for treatment of liver cancer

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Sep 30, 2016
Commencement of First in Human Immunotherapy Study Using Gold Nanoparticle Technology

Midatech (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in... read more >

Sep 21, 2016
Midatech Pharma US Announces Partnership with R-Pharm US to Co-promote Zuplenz® (ondansetron) oral soluble film and Oravig® (miconazole) orally-dissolving buccal tablet

~ Partnership provides additional reach and frequency within the oncology market ~

~ Deal broadens Zuplenz... read more >

Sep 2, 2016
Interim results for the six months ended 30 June 2016

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Aug 10, 2016
Trading Update and Notice of Results

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Jul 7, 2016
Grant funding received to explore Midatech’s gold nanoparticle technology in immunotherapy

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

May 18, 2016
Midatech Pharma announces clinical pipeline update

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), today announces an update on its clinical pipeline developments.
 
Midatech is working on... read more >

May 11, 2016
AGM Statement and Update on Trading

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), today will host its Annual General Meeting at Panmure Gordon & Co, One New Change, London, EC4M... read more >

Apr 26, 2016
Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide

~ Release profile of Midatech’s Q-Octreotide compared favourably with the reference product and current market... read more >

Apr 21, 2016
Midatech achieves positive dosing data for OpsiSporin Uveitis programme

~ Programme is delivering on track for an IND in H2 2017 ~

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the... read more >

Apr 13, 2016
Audited financial results for the year ended 31 December 2015

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Apr 11, 2016
Midatech’s Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US

~ Midatech further expands its commercial footprint in US, supporting the Zuplenz® launch ~

Midatech Pharma... read more >

Feb 29, 2016
Midatech Pharma Recognises International Rare Disease Day 2016

~ Dosing has commenced with MTX110 for DIPG on a named patient basis ~

Midatech Pharma (AIM: MTPH, Nasdaq:... read more >

Jan 6, 2016
Pre-close Trading Update

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Jan 4, 2016
Midatech signs licencing agreement with Emergex Vaccines

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

© Copyright 2017 Midatech Pharma PLC